Navigation Links
Gen-Probe Reports Financial Results for the Second Quarter of 2011
Date:7/28/2011

the prior year period, a decrease of 61% that resulted primarily from an expected decrease in funding from Novartis associated with the development of the fully automated PANTHER instrument for the blood screening market.

Royalty and license revenues in the second quarter of 2011 were $1.4 million, compared to $1.8 million in the prior year period.  

GAAP Income Statement DetailsGross margin on product sales was 70.3% in the second quarter of 2011, compared to 66.6% in the prior year period.  This increase resulted mainly from a favorable product sales mix, namely higher sales of APTIMA products and lower sales of instrumentation to Novartis.  

Acquisition-related amortization expenses were $2.7 million in the second quarter of 2011, compared to $2.2 million in the prior year period, an increase of 23% that resulted mainly from the acquisition of GTI in December of 2010.

Research and development (R&D) expenses were $27.7 million in the second quarter of 2011, compared to $27.1 million in the prior year period, an increase of 2% that resulted primarily from the addition of GTI's R&D programs.  

Marketing and sales expenses were $17.5 million in the second quarter of 2011, compared to $15.8 million in the prior year period, an increase of 11% that resulted primarily from the addition of GTI's cost structure, and ongoing European commercial expansion.  

General and administrative (G&A) expenses were $18.7 million in the second quarter of 2011, compared to $15.0 million in the prior year period, an increase of 25% that resulted from the addition of GTI's cost structure, increased legal expenses, and higher stock-based compensation.  

Total other income, net, was $3.8 million in the second quarter of 2011, compared to $6.9 million in the prior year period, a decrease of 45% that resulted primarily from a non-cash gain in the prior year period related to a change in the fair val
'/>"/>

SOURCE Gen-Probe Incorporated
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14

Related biology technology :

1. Gen-Probe to Webcast Presentation at the Thomas Weisel Partners Healthcare Conference 2008
2. Gen-Probe to Webcast Presentation at the Morgan Stanley Global Healthcare Unplugged Conference
3. Gen-Probe to Webcast Presentation at the Bank of America 38th Annual Investment Conference
4. Gen-Probe to Webcast Presentation at the UBS Global Life Sciences Conference
5. Gen-Probe to Webcast Presentation at the Lazard Capital Markets 5th Annual Healthcare Conference
6. Promising Clinical Data on Gen-Probes APTIMA(R) HPV Test Presented at Major European Medical Meeting
7. Gen-Probe Announces Webcast of Fourth Quarter and Full Year 2008 Earnings Conference Call
8. Eric Lai Joins Gen-Probe as Senior Vice President, Research and Development
9. Gen-Probe Borrows $170 Million Under New Line of Credit
10. Gen-Probe to Webcast Two Upcoming Investor Presentations
11. Gen-Probe Completes Acquisition of Tepnel Life Sciences
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/27/2015)... , 27. März 2015  Peter ... in Biomedical Science für seine bahnbrechende Arbeit ... zwischen Zellkompartimenten transportiert werden, sowie für die ... zur Reaktion auf Stress nutzen, der mit ... Walter ist Professor für Biochemie an der ...
(Date:3/27/2015)... , March 27, 2015   SurePure, Inc ... photopurification, announced today that the Company has completed ... continued trading of SurePure ("SURP") securities on OTCQB, ... for entrepreneurial and development stage companies. ... standards and eligibility requirements designed to improve marketplace ...
(Date:3/27/2015)... March 27, 2015 Working in collaboration ... in London , Richmond Pharmacology is the ... Phase 3 study for an investigational RNAi therapeutic being developed ... affecting the nerves and heart. Read press ... Based at St Georges University of ...
(Date:3/27/2015)... 27, 2015  CASI Pharmaceuticals, Inc. (Nasdaq: CASI ... and commercialization of innovative therapeutics addressing cancer and other ... commercial focus on China , today ... ended December 31, 2014.  The Company ... per share, for the three months ended December 31, ...
Breaking Biology Technology:Deutschstämmiger Zellbiologe Peter Walter gewinnt den Vilcek Prize in Biomedical Science 2015 2Deutschstämmiger Zellbiologe Peter Walter gewinnt den Vilcek Prize in Biomedical Science 2015 3Deutschstämmiger Zellbiologe Peter Walter gewinnt den Vilcek Prize in Biomedical Science 2015 4SurePure Completes Verification and Approved for Trading on the OTCQB Marketplace 2CASI Pharmaceuticals Reports 2014 Fourth Quarter And Full Year Financial Results 2CASI Pharmaceuticals Reports 2014 Fourth Quarter And Full Year Financial Results 3CASI Pharmaceuticals Reports 2014 Fourth Quarter And Full Year Financial Results 4CASI Pharmaceuticals Reports 2014 Fourth Quarter And Full Year Financial Results 5CASI Pharmaceuticals Reports 2014 Fourth Quarter And Full Year Financial Results 6
... smaller and more complex every year. It turns out that ... to small devices, such as cell phones, hitting the floor. ... when dropped? , A team of Clemson University researchers, led ... to make beds of tiny, shock-absorbing carbon springs which possibly ...
... N.J., Aug. 13 At the upcoming Medical,Grade ... Team,Leader, will present "Silicone Elastomer Gels: New Soft ... in Philadelphia, September 16-17., According to Dr. ... that provide differentiated performance features for wound care,scar ...
... MS, - Milestone triggers $10 million payment ... Aug. 13 /PRNewswire-FirstCall/ - BioMS Medical Corp. (TSX:,MS), ... sclerosis (MS), today,announced that the independent Drug Safety ... the scheduled interim analysis of efficacy,and safety and ...
Cached Biology Technology:Clemson scientists put a (nano) spring in their step 2Bluestar Silicones Presents Adhesive Gels for Wound Care at Medical Grade Polymers Conference 2BioMS Medical announces positive interim analysis on phase III trial of dirucotide (MBP8298) for multiple sclerosis 2BioMS Medical announces positive interim analysis on phase III trial of dirucotide (MBP8298) for multiple sclerosis 3BioMS Medical announces positive interim analysis on phase III trial of dirucotide (MBP8298) for multiple sclerosis 4
(Date:3/16/2015)... 16, 2015 Between 16 ... present groundbreaking innovations in biometric identification at the ... .      (Photo: http://photos.prnewswire.com/prnh/20150316/735333 ... is well at the forefront: the company,s all ... in Germany . BiometricGate is ...
(Date:3/12/2015)... VIEW, Calif. , March 12, 2015 /PRNewswire/ ... with Complimentary Registration here: http://bit.ly/1G7Os0L . SPEAKERS: ... Manager Aravind SeshagiriPhoto - http://photos.prnewswire.com/prnh/20150311/181111 ... in order to compete in several different markets ... market is currently witnessing an uptrend. ...
(Date:3/10/2015)... March 10, 2015 Transforming How ... "Personalized Medicine in Human Space Flight" by ... J. Goodwin , Ph.D. was recently featured by Springer ... two years. Specifically, "Personalized Medicine in Human ... papers published in 2013 and 2014 from Springer in ...
Breaking Biology News(10 mins):DERMALOG Presents its Latest Biometric Innovations at the Hannover CeBIT Exhibition, 16 - 20 March 2015 2DERMALOG Presents its Latest Biometric Innovations at the Hannover CeBIT Exhibition, 16 - 20 March 2015 3Biometrics Key to Future Growth in Healthcare, Retail and Financial Markets 2Biometrics Key to Future Growth in Healthcare, Retail and Financial Markets 3"Personalized Medicine in Human Space Flight" Listed Among Most Influential Papers of 2013 and 2014 2
... WAYNE, Pa., Dec. 14 MODA Technology Partners, a ... and product testing for the Pharmaceutical industry, today announced ... generation mobile data acquisition platform. The latest release enables ... manufacturing processes. , MODA 3.0 includes the following ...
... team led by Yale University researchers has used nanosensors ... first time. Their findings, which appear December 13 in ... could dramatically simplify the way physicians test for biomarkers ... teamled by Mark Reed, Yale,s Harold Hodgkinson Professor of ...
... increases, growers are being challenged to bring consistently ... bottom line, orchard owners are experimenting with new ... labor costs. Hand thinning, a common practice ... is among the most labor-intensive of orchard practices, ...
Cached Biology News:MODA Announces Availability of Third Generation Mobile Data Acquisition Platform 2Scientists use nanosensors for first time to measure cancer biomarkers in blood 2Horizontal string trimmer reduces labor costs, increases peach size 2
...
1, 2 or 8 PreMixes are included as part of the FailSafe™ PCR System....
2ndGen Predilute antibody for staining tissue sections. Optimized for use with Zymeds Histostain-PLUS, NBA, HistoST5050, and Cap-Plus IHC Kits.Labeling: ASR...
Reactivity: Human...
Biology Products: